Peptide Stapling: Locking Helical Shape for Potency

Peptide Stability and Modification

40x protease resistance

Hydrocarbon-stapled BH3 peptides showed up to 40-fold greater resistance to proteolytic degradation compared to their unstapled counterparts.

Walensky et al., Science, 2004

Walensky et al., Science, 2004

View as image

Short peptides fold and unfold thousands of times per second in solution. That constant motion exposes their backbone to proteases and prevents them from holding the exact shape needed to bind a protein target. Peptide stapling solves both problems at once by installing a covalent chemical bridge, called a staple, between two amino acid side chains on the same face of an alpha helix.^[1] The result is a peptide locked into its helical shape, resistant to enzymatic breakdown, and often capable of entering cells. For readers interested in how this fits into the broader peptide stabilization toolkit, see our overview on cyclization and ring-based stabilization strategies.

What peptide stapling actually does to structure

An unmodified peptide of 10 to 20 amino acids in water rarely holds a stable alpha-helical fold. The entropy cost of ordering the backbone is too high relative to the stabilizing hydrogen bonds that define the helix. Peptide stapling shifts this balance by introducing a covalent crosslink between two residues positioned on the same face of the helix.^[2]

The crosslink physically prevents the backbone from unfolding. In circular dichroism measurements, stapled peptides routinely show alpha-helical content above 80%, compared to 10-30% for the equivalent linear sequences.^[3] That pre-organized shape reduces the entropic penalty of binding: the peptide does not need to fold upon contact with its target, so the free energy of association improves.

The practical consequence is tighter binding. Chang et al. reported that a stapled alpha-helical peptide (ATSP-7041) targeting both MDM2 and MDMX achieved binding affinities in the low-nanomolar range, roughly 1,000 times stronger than the unstapled parent sequence.^[4] That improvement comes almost entirely from conformational preorganization, not from the staple itself making direct contact with the protein surface.

How the hydrocarbon staple is built

The most widely used stapling method, developed by Schafmeister, Po, and Verdine in 2000, relies on ring-closing olefin metathesis (RCM). Two non-natural amino acids bearing olefin-tipped side chains replace natural residues at positions i, i+4 (spanning one helical turn) or i, i+7 (spanning two turns). A ruthenium catalyst, typically a Grubbs-type catalyst, then joins the two olefin tails into a single hydrocarbon bridge.^[2]

Bird et al. published a detailed synthesis protocol in 2011, establishing standard conditions for solid-phase peptide synthesis followed by on-resin RCM. The reaction typically proceeds in dichloromethane or 1,2-dichloroethane at room temperature, with stapling yields above 80% for optimized sequences.^[5]

The chemistry matters because the all-hydrocarbon bridge is metabolically inert. Unlike disulfide bridges, which can be reduced by glutathione inside cells, or lactam bridges, which contain an amide bond susceptible to certain proteases, the carbon-carbon bonds in a hydrocarbon staple resist enzymatic cleavage. This chemical stability translates directly into biological half-life. This advantage parallels the stability gains seen with other backbone modification strategies like N-methylation and PEGylation.

Beyond hydrocarbon: alternative stapling chemistries

Hydrocarbon stapling via RCM dominates the literature, but several alternative chemistries have emerged, each with trade-offs.

Lactam stapling connects lysine and glutamic acid (or aspartic acid) side chains through an amide bond at i, i+4 positions. Klein et al. showed that lactam-stapled cell-penetrating peptides achieved cellular uptake rates 3 to 5 times higher than linear equivalents, with enhanced membrane binding properties demonstrated by solid-state NMR.^[6] The advantage: lactam stapling uses standard amino acids and does not require specialized non-natural building blocks. The drawback: the amide bond in the staple is itself a potential protease substrate, limiting proteolytic stability gains compared to all-hydrocarbon crosslinks.

Thioether stapling uses cysteine side chains linked through thioether bonds. This approach is compatible with recombinant peptide production, making it attractive for large-scale manufacturing.

Double stapling applies two crosslinks to longer peptides. A 2024 Nature Communications study by Chandramohan et al. established computational design rules for double-stapled peptides targeting the MDM2/MDMX interface, demonstrating that staple placement could be optimized by molecular dynamics simulations to predict in vivo activity before synthesis.^[7] The double-stapled Mdm2/X antagonist achieved tumor regression in xenograft models at doses where single-stapled analogs were inactive.

Li et al. provided the most comprehensive catalog of anchoring residue chemistries in a 2020 Chemical Reviews article spanning over 60 pages, covering hydrocarbon, lactam, triazole, thioether, disulfide, and hybrid stapling methods. For a broader perspective on how stapled peptides fit alongside other constrained formats, see our article on macrocyclic peptides.^[3]

Three things stapling improves simultaneously

Protease resistance

Walensky et al.'s 2004 Science paper, the study that catalyzed the field, demonstrated that a hydrocarbon-stapled BH3 peptide resisted proteolytic degradation for over 24 hours in serum, while the linear parent peptide was completely degraded within one hour.^[8] The staple physically blocks protease access to the backbone amide bonds by both steric shielding and by holding the backbone in a conformation that does not fit typical protease active sites. This mechanism is distinct from the approach used in D-amino acid substitution, which achieves protease resistance through stereochemical inversion rather than conformational locking.

Cell permeability

Linear peptides larger than roughly 5 amino acids generally cannot cross cell membranes passively. Stapled peptides break this rule. The hydrocarbon bridge increases overall hydrophobicity, and the locked helical shape presents a defined amphipathic surface: one hydrophobic face (including the staple) contacts the lipid bilayer, while the hydrophilic face remains solvent-exposed. Multiple studies have demonstrated stapled peptide internalization via both energy-dependent (endocytosis) and energy-independent (direct translocation) mechanisms.^[1]

Target affinity

The pre-organized helix eliminates the conformational search that a flexible peptide must perform before binding. For protein-protein interactions mediated by helical interfaces, which represent an estimated 40% of all protein-protein interactions, this translates to binding improvements of 10- to 1,000-fold.^[4]

These three improvements are interconnected. A stapled peptide that resists degradation reaches its target at higher concentration, binds more tightly once there, and can access intracellular targets that linear peptides cannot reach.

From bench to clinic: the ALRN-6924 story

The most advanced clinical program for a stapled peptide is sulanemadlin (ALRN-6924), developed by Aileron Therapeutics. Guerlavais et al. published the full discovery story in 2023, documenting the optimization journey from a 12-residue p53 activation domain peptide to a drug candidate that entered Phase 2 trials.^[9]

ALRN-6924 targets both MDM2 and MDMX, the two primary negative regulators of the tumor suppressor p53. In wild-type p53 cancers, these proteins keep p53 inactive. ALRN-6924 disrupts both interactions simultaneously, releasing p53 to trigger apoptosis in cancer cells. The dual-targeting capability is a direct consequence of the stapled helical structure, which mimics the alpha-helical transactivation domain of p53 that binds both MDM2 and MDMX.^[4]

In Phase 1 trials, ALRN-6924 was well tolerated at doses that achieved plasma concentrations above the predicted efficacy threshold. The clinical program has explored two distinct applications: as a direct antitumor agent in MDM2-amplified cancers, and as a chemoprotective agent that transiently arrests wild-type p53 cells to shield them from chemotherapy damage while p53-mutant tumor cells remain vulnerable.^[9]

Before ALRN-6924, Aileron completed Phase 1 testing of ALRN-5281, a stapled peptide growth hormone-releasing hormone (GHRH) agonist, in 2013. That study demonstrated the basic pharmacokinetic viability of stapled peptides in humans: a single subcutaneous injection produced sustained growth hormone elevation for several days, consistent with the extended half-life predicted from preclinical protease resistance data.^[1]

Disease applications beyond cancer

Infectious disease

Curreli et al. designed stapled peptides based on the alpha-helical region of human ACE2 that binds the SARS-CoV-2 spike protein. The best analog inhibited viral infection in vitro at low-micromolar concentrations, demonstrating that stapled peptides can function as competitive inhibitors of viral entry. The stapled ACE2 mimics were resistant to trypsin degradation and remained active after 24 hours of incubation in human serum.^[10]

Antimicrobial applications

Shao et al. created ultrashort (8-residue) all-hydrocarbon stapled amphipathic helices that killed multidrug-resistant bacteria at concentrations below 4 micrograms per milliliter, comparable to conventional antibiotics. The stapled peptides showed minimal hemolytic activity, addressing a longstanding toxicity concern with antimicrobial peptides.^[11] In a systematic study, Shi et al. applied all-hydrocarbon stapling to 13 positions along cecropin A and identified an analog (CecA-S7) 16-fold more potent against E. coli than the parent peptide, with an MIC of 0.25 micrograms per milliliter.^[12]

Metabolic disease

Zhou et al. reported a stapled GLP-1R/GIPR/GCGR triple agonist in 2025 that combined stapling with lipidation to produce a long-acting metabolic peptide. In diet-induced obese mice, it reduced body weight by 30.7% over 28 days with once-weekly dosing, outperforming individual receptor agonists.^[13] This application illustrates how stapling can be combined with other half-life extension strategies to create peptides with drug-like pharmacokinetics.

Wound healing

Chen et al. published 2026 data on stapled peptide inhibitors targeting the VGLL4/TEAD4 protein-protein interaction, showing accelerated cutaneous wound healing in mouse models. The stapled peptides activated YAP/TAZ signaling to promote keratinocyte proliferation and migration.^[14]

Design rules and computational prediction

Rational staple placement is critical. Placing the staple on the wrong face of the helix can block the binding interface; placing it at the wrong register can destabilize the helix rather than reinforce it.

Chandramohan et al.'s 2024 work in Nature Communications established the most rigorous design rules to date. Using a combination of molecular dynamics simulations and experimental validation across 82 stapled peptide variants, they identified three predictive factors for in vivo activity: (1) solvent-exposed staple placement that avoids the binding interface, (2) helical content above 60% as measured by circular dichroism, and (3) a cell permeability score derived from calculated polar surface area.^[7]

These computational approaches are reducing the trial-and-error traditionally required to optimize stapled peptides. The same group demonstrated that their design rules predicted which of 20 novel stapled peptide designs would show in vivo tumor regression, correctly identifying the active compounds before synthesis.

What stapling cannot do

Stapling is not a universal solution. Several limitations constrain its applicability.

Size constraints. The target interaction must involve an alpha-helical interface. Beta-sheet, loop, or disordered binding motifs are not amenable to helical stapling. Roughly 60% of known protein-protein interactions involve non-helical interfaces, placing them outside the reach of standard stapling approaches.^[1]

Manufacturing complexity. The non-natural amino acids required for hydrocarbon stapling are expensive and not commercially available at the scale needed for large clinical programs. Lactam stapling avoids this problem but sacrifices some metabolic stability. Peptide synthesis at GMP quality adds cost and time compared to small-molecule drugs or recombinant biologics.

Oral bioavailability remains elusive. While stapled peptides resist proteolytic degradation far better than linear peptides, oral absorption through the intestinal epithelium remains limited for most stapled peptide designs. Most clinical programs use injectable formulations. The cyclization strategies used by naturally occurring cyclic peptides like cyclosporine A have achieved oral bioavailability, but translating those principles to stapled helical peptides remains an active area of research.

Cell permeability is not guaranteed. Not all stapled peptides enter cells efficiently. Staple placement, overall charge, and amphipathicity all influence membrane crossing. Some stapled peptides accumulate in endosomes rather than reaching the cytoplasm, limiting their ability to engage intracellular targets.^[6]

Clinical track record is thin. Only two stapled peptides have entered clinical trials as of early 2026. The technology has generated compelling preclinical data across oncology, infectious disease, and metabolic disorders, but long-term human safety and efficacy data remain limited.

The Bottom Line

Peptide stapling locks alpha-helical structure through a covalent chemical bridge, simultaneously improving protease resistance, cell permeability, and target binding affinity. The technology has produced one Phase 2 clinical candidate (sulanemadlin/ALRN-6924) and preclinical candidates across oncology, infectious disease, antimicrobial, and metabolic applications. The primary limitations are manufacturing cost, restriction to helical binding interfaces, and a still-thin clinical track record.

Frequently Asked Questions

What is a stapled peptide?

A stapled peptide is a modified peptide locked into an alpha-helical shape by a covalent chemical bridge between two amino acid side chains. The bridge, called a staple, prevents the peptide from unfolding, which improves its stability against enzymatic breakdown, increases its ability to enter cells, and strengthens its binding to protein targets. The most common staple type is an all-hydrocarbon crosslink formed by ring-closing olefin metathesis.

How does peptide stapling improve drug stability?

Stapling improves stability through two mechanisms. First, the covalent bridge physically prevents proteases from accessing the backbone amide bonds by steric shielding. Second, the locked helical conformation does not fit the active sites of most proteases, which typically require an extended peptide substrate. Walensky et al. demonstrated in 2004 that hydrocarbon-stapled BH3 peptides survived over 24 hours in serum while unstapled versions degraded within one hour.

What is the difference between hydrocarbon stapling and lactam stapling?

Hydrocarbon stapling uses non-natural amino acids with olefin side chains joined by ruthenium-catalyzed ring-closing metathesis, creating a carbon-carbon bridge that resists enzymatic cleavage. Lactam stapling connects lysine and glutamic acid side chains through an amide bond. Lactam staples use standard amino acids and are simpler to synthesize, but the amide bond in the staple itself can be cleaved by proteases, providing less metabolic stability than the all-hydrocarbon approach.

Are stapled peptides FDA approved?

No stapled peptide has received FDA approval as of early 2026. The most advanced candidate, sulanemadlin (ALRN-6924) from Aileron Therapeutics, has completed Phase 1 and entered Phase 2 trials for p53-dependent cancers. ALRN-5281, a stapled GHRH agonist, completed Phase 1 testing in 2013. The technology remains in clinical development with no approved products on the market.

What diseases can stapled peptides treat?

Stapled peptides are being investigated across multiple disease areas. The furthest-advanced clinical program targets p53-dependent cancers by disrupting the MDM2/MDMX interaction. Preclinical research spans infectious disease (SARS-CoV-2 entry inhibition), antimicrobial applications (multidrug-resistant bacteria), metabolic disease (GLP-1 receptor triple agonists for obesity), and wound healing. The technology is best suited to diseases driven by protein-protein interactions that involve alpha-helical binding interfaces.

How are stapled peptides made?

The standard hydrocarbon stapling method uses solid-phase peptide synthesis to build the peptide chain, incorporating two non-natural amino acids with olefin-bearing side chains at specific positions. A ruthenium-based Grubbs catalyst then performs ring-closing olefin metathesis on the resin, joining the two olefin tails into a single hydrocarbon bridge. The stapled peptide is then cleaved from the resin and purified. Bird et al. published a detailed synthesis protocol in 2011 with yields above 80% for optimized sequences.